Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - A systematic review of the evidence from randomized trials

European Journal of Gynaecological Oncology

Volumn 23, Issue 2, 2002, Pages 104-110

  Fung Kee Fung, M ^a   Johnston, M E ^a   Eisenhauer, E A ^a   Elit, L ^a   Hirte, H W ^a   Rosen, B ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Chemotherapy; Ovarian cancer; Platinum; Recurrent

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; OXALIPLATIN; PACLITAXEL; PLATINUM; TOPOTECAN; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; MEDLINE; OVARY CANCER; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SURVIVAL TIME; OVARY TUMOR; PALLIATIVE THERAPY; REVIEW; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; PLATINUM COMPOUNDS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 0036010329     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chemotherapy of advanced ovarian cancer
2. Treatment of recurrent ovarian cancer: Increasing options "Recurrent" results
3. Palliative therapy in advanced ovarian cancer: Balancing patient expectations, quality of life and cost
4. Attitudes to chemotherapy: Comparing views of doctors, nurses, and general public
5. Treatment for recurrent or progressive ovarian cancer failing first-line chemotherapy: A review of systemic treatment modalities
6. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
7. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A gynecologic oncology group study
8. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A gynecologic oncology group study
9. Topotecan in the treatment of advanced recurrent epithelial ovarian cancer
10. Gemcitabine in ovarian cancer: An overview of safety and efficacy
11. Gemcitabine in platin-paclitaxel resistant ovarian carcinoma
12. Phase II study of gemcitabine in ovarian cancer
13. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
14. The promise of targeted novel chemotherapy in solid tumors
15. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
16. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
17. Randomized phase II study of two schedules on topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
18. Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer?
19. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line chemotherapy for cisplatin- or carboplatin-sensitive ovarian cancer
20. Paclitaxel vs cap (cyclophosphamide, adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: A randomized phase II study
21. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
22. Final analysis of a phase III study of topotecan vs paclitaxel in advanced epithelial ovarian carcinoma
23. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
24. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
25. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and-resistant ovarian cancer
26. Randomized trial comparing paclitaxel+doxorubicin versus paclitaxel as second line therapy for advanced ovarian cancer patients in early progression after platinum based chemotherapy
27. The palliative effect of chemotherapy: Objective tumor response correlates with symptom improvement in patients with metastatic breast cancer
28. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
29. Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy
30. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and design of phase II trials
31. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer